TRCT
QTTB icon

Tower Research Capital (TRC)’s Q32 Bio QTTB Stock Holding History

Tower Research Capital (TRC)’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,871
Closed -$12K – 5729
2026
Q1 		$12K Buy
1,871
+895
+92% +$4.25K ﹤0.01% 3811
2025
Q4 		$3.24K Sell
976
-5,506
-85% -$15.6K ﹤0.01% 4400
2025
Q3 		$12.8K Buy
6,482
+230
+4% +$442 ﹤0.01% 3745
2025
Q2 		$9.31K Buy
6,252
+3,075
+97% +$5.24K ﹤0.01% 3994
2025
Q1 		$5.24K Buy
3,177
+1,701
+115% +$4.58K ﹤0.01% 4139
2024
Q4 		$5.08K Buy
1,476
+1,284
+669% +$40.5K ﹤0.01% 4354
2024
Q3 		$8.57K Sell
192
-2,010
-91% -$73.9K ﹤0.01% 3953
2024
Q2 		$39.5K Buy
+2,202
New +$52.7K ﹤0.01% 3275
2023
Q4 		– Sell
-18
Closed -$371 – 6211
2023
Q3 		$371 Buy
+18
New +$367 ﹤0.01% 5585
2023
Q2 		– Sell
-133
Closed -$2K – 6407
2023
Q1 		$2K Sell
133
-864
-87% -$21.5K ﹤0.01% 5417
2022
Q4 		$23K Buy
997
+658
+194% +$17.5K ﹤0.01% 3016
2022
Q3 		$10K Sell
339
-48
-12% -$1.96K ﹤0.01% 4584
2022
Q2 		$14K Buy
387
+204
+111% +$6.96K ﹤0.01% 4174
2022
Q1 		$10K Sell
183
-1,291
-88% -$80.2K ﹤0.01% 4369
2021
Q4 		$96K Buy
1,474
+1,412
+2,277% +$137K ﹤0.01% 2248
2021
Q3 		$8K Sell
62
-124
-67% -$15.8K ﹤0.01% 4577
2021
Q2 		$24K Buy
186
+1
+0.5% +$125 ﹤0.01% 3741
2021
Q1 		$32K Sell
185
-16
-8% -$3.37K ﹤0.01% 3527
2020
Q4 		$41K Sell
201
-1,331
-87% -$257K ﹤0.01% 3310
2020
Q3 		$296K Buy
1,532
+987
+181% +$221K ﹤0.01% 2204
2020
Q2 		$149K Buy
+545
New +$145K 0.01% 2079
2020
Q1 		– Sell
-184
Closed -$69K – 4037
2019
Q4 		$69K Buy
184
+147
+397% +$42.1K 0.01% 1144
2019
Q3 		$12K Buy
+37
New +$12.6K ﹤0.01% 2841
2019
Q2 		– Sell
-27
Closed -$14K – 4405
2019
Q1 		$14K Buy
+27
New +$12.1K ﹤0.01% 2489

Other funds holding QTTB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s QTTB Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Q32 Bio (QTTB) in Q2 2026, closing a stake of 1,871 shares — an estimated $12K sold.

Tower Research Capital (TRC) first reported a position in QTTB in Q1 2019 and held it in 24 quarters. The position peaked at $296K in Q3 2020. 72 funds tracked by Wall St. Rank hold QTTB as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Q32 Bio position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,871 Q32 Bio shares in Q2 2026, an estimated $12K.
  • Tower Research Capital (TRC) first reported a position in Q32 Bio in Q1 2019 and held it in 24 quarters.
  • Tower Research Capital (TRC)'s Q32 Bio position peaked at $296K in Q3 2020.
  • 72 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.